Drug Trial Radar · NCT07209761
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
532
Planned (sponsor's estimate)
Start
Oct 16, 2025
Primary completion
Sep 29, 2028
Study completion Sep 29, 2028
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or multidrug-resistant pulmonary tuberculosis. Participants are assigned to 1 of 2 cohorts based on fluoroquinolone susceptibility. In the fluoroquinolone-susceptible cohort, participants are randomized 1:1 to receive either a 4-month experimental regimen of bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin. In the fluoroquinolone-resistant cohort, participants are randomized 3:1 to receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. A total of approximately 532 participants are planned, including 432 participants in the fluoroquinolone-susceptible cohort and approximately 100 participants in the fluoroquinolone-resistant cohort. The primary efficacy endpoint is the proportion of participants with an unfavorable outcome by 12 months post-randomization. Prespecified agency-specific definitions are used for the classification of regimen changes, sputum culture conversion, relapse, and reinfection. All unfavorable outcome events will be confirmed by a blinded Endpoint Adjudication Committee.
Conditions
- Rifampicin-Resistant Pulmonary Tuberculosis
- Multidrug-Resistant Pulmonary Tuberculosis
Interventions
BedaquilineDrug
In the BPaQM and BPaQ experimental arms, bedaquiline is administered orally at 400 mg once daily for 2 weeks, followed by 100 mg once daily for 15 weeks in the BPaQM arm or 24 weeks in the BPaQ arm. In the BPaLM and BPaL control arms, bedaquiline is administered orally at 400 mg once daily for 2 weeks, followed by 200 mg 3 times weekly for 24 weeks.
QuabodepistatDrug
Quabodepistat 30 mg administered orally once daily under fed conditions, during or immediately after a meal. Quabodepistat is administered for 4 months, with a target of 120 treatment days, in the BPaQM arm and for 6 months, with a target of 180 treatment days, in the BPaQ arm.
PretomanidDrug
Pretomanid 200 mg administered orally once daily for 4 months in the BPaQM arm and for 6 months in the BPaLM, BPaQ, and BPaL arms.
MoxifloxacinDrug
Moxifloxacin 400 mg administered orally once daily for 4 months in the BPaQM arm and for 6 months in the BPaLM arm.
LinezolidDrug
Linezolid 600 mg administered orally once daily for 6 months in the BPaLM and BPaL arms. Protocol-defined dose reduction to 300 mg once daily, temporary interruption, or discontinuation may be permitted to manage significant toxicity after consultation with the medical monitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with an unfavorable outcome by 12 months post-randomization.Time frame: From randomization through 12 months post-randomization.
- Proportion of participants with significant treatment-emergent adverse events (TEAEs) during treatment and through 2 weeks after treatment.Time frame: From the first dose through 2 weeks after the end of treatment, up to approximately 28 weeks.
Locations
42 sites in 10 countries. Site status is shown where the registry gives one.
Capital Medical University - Beijing Chest Hospital
Beijing, Beijing Municipality, China · Recruiting
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province
Fuzhou, Fujian, China · Recruiting
The Third People's Hospital of Shenzhen
Shenzhen, Guangdong, China · Recruiting
Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital)
Wuhan, Hubei, China · Recruiting
The Second Hospital of Nanjing
Nanjing, Jiangsu, China · Recruiting
Shandong Public Health Clinical Center
Jinan, Shandong, China · Recruiting
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital - Pneumology
Shanghai, Shanghai Municipality, China · Recruiting
Public Health Clinical Center of Chengdu
Chengdu, Sichuan, China · Recruiting
National Center for Tuberculosis and Lung Disease
Tbilisi, Georgia · Recruiting
P.D. Hinduja Hospital & Medical Research Centre - MAHIM
Mumbai, Maharashtra, India · Not yet recruiting
Rajan Babu Institute of Pulmonary Medicine and Tuberculosis (RBIPMT) - RBTB Hospital
New Delhi, National Capital Territory of Delhi, India · Not yet recruiting
National Institute of Tuberculosis and Respiratory Diseases Hospital (NITRD)
New Delhi, National Capital Territory of Delhi, India · Not yet recruiting
Indian Council of Medical Research (ICMR) - National Institute for Research in Tuberculosis (NIRT) (Tuberculosis Research Centre)
Chennai, Tamil Nadu, India · Not yet recruiting
Jakarta Islamic Hospital - Rumah Sakit Islam Jakarta (RSIJ)
Jakarta, Special Capital Region of Jakarta, Indonesia · Not yet recruiting
Rumah Sakit Umum Pusat (RSUP) Dr. Hasan Sadikin
Bandung, West Java, Indonesia · Not yet recruiting
Rumah Sakit Paru Dr. M. Goenawan Partowidigdo (RSPG)
Bogor, West Java, Indonesia · Not yet recruiting
Japan Anti-Tuberculosis Association Fukujuji Hospital
Kiyose, Tokyo, Japan · Recruiting
IMSP Institutul de Ftiziopneumologie Chiril Draganiuc - Phthisiopneumology
Chisinau, Chisinau City, Moldova · Recruiting
Hospital Sergio E. Bernales
Lima, Peru · Recruiting
Socios en Salud Sucursal Peru
La Molina, Lima region, Peru · Recruiting
Centro de Investigación del Hospital de Emergencias de Villa el Salvador
Villa El Salvador, Lima region, Peru · Not yet recruiting
Silang Specialist Medical Center
Silang, Cavite, Philippines · Recruiting
Tropical Disease Foundation
Makati City, National Capital Region, Philippines · Recruiting
Lung Center Of The Philippines
Quezon City, National Capital Region, Philippines · Recruiting
Rafael Lazatin Memorial Medical Center
Angeles City, Pampanga, Philippines · Recruiting
Synergy Biomed Research Institute
East London, Eastern Cape, South Africa · Recruiting
Isango Lethemba TB Res Unit (CHRU) - Jose Pearson TB Hospital
Port Elizabeth, Eastern Cape, South Africa · Recruiting
The Aurum Institute - Tembisa Hospital Clinical Research Centre
Johannesburg, Gauteng, South Africa · Recruiting
Clinical HIV Research Unit (CHRU) - Helen Joseph Hospital
Johannesburg, Gauteng, South Africa · Recruiting
Sizwe Clinical Research Site (CHRU) - Sizwe Tropical Disease Hospital,
Johannesburg, Gauteng, South Africa · Recruiting
Setshaba Research Center
Pretoria, Gauteng, South Africa · Withdrawn
Perinatal HIV Research Unit (PHRU) - Chris Hani Baragwanath Academic Hospital
Soweto, Gauteng, South Africa · Recruiting
Centre for the AIDS Programme of Research in South Africa (CAPRISA)
Durban, KwaZulu-Natal, South Africa · Recruiting
Klerksdorp/Tshepong Hospital Complex, Tshepong Hospital, MDR Unit
Klerksdorp, North West, South Africa · Recruiting
The Aurum Institute - Rustenburg
Rustenburg, North West, South Africa · Recruiting
Brooklyn Chest Hospital
Belville, Western Cape, South Africa · Recruiting
UCT - Lung Infection and Immunity Unit
Cape Town, Western Cape, South Africa · Recruiting
UCT Lung Institute
Cape Town, Western Cape, South Africa · Recruiting
The Catholic University of Korea, Incheon St. Mary's Hospital
Incheon, Incheon Metropolitan City, South Korea · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.